Please login to the form below

Not currently logged in
Email:
Password:

Novel HIV treatment shows promise

Myriad Pharmaceuticals' HIV treatment MPC-4326 "safe and well tolerated"

Myriad Pharmaceuticals' HIV treatment MPC-4326 is safe and well tolerated according to two abstracts presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting on 12–15 September in San Francisco, US.

MPC-4326 is the first 'maturation inhibitor' a new class of HIV drug that inhibits the final step in the processing of the HIV Gag protein. Treatments with novel mechanism of action are though to be critical to combat drug resistance to available HIV therapies.

"I am very excited that the new 100 mg tablet formulation of MPC-4326 has performed so well," said Dr Adrian Hobden, President and CEO of the Salt Lake City-based biopharmaceutical company. "Coupled with the potential companion diagnostic and the significant viral load reductions seen in these two studies, we believe that we have a clear clinical path forward."

15th September 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics